The return of Ehrlich's 'Therapia magna sterilisans' and other Ehrlich concepts? Series of papers honoring Paul Ehrlich on the occasion of his 150th birthday

Chemotherapy

Volumn 50, Issue 1, 2004, Pages 6-10

  Sorgel F ^a,b  

^a Institute for Biomedical and Pharmaceutical Research   (Germany)

^b IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

Author keywords

Antibiotics; Dyes; Paul Ehrlich; Syphilis; Therapia magna sterilisans

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ARSENIC; ARSENIC TRIOXIDE; ARSPHENAMINE; AZITHROMYCIN; BENZATHINE PENICILLIN; BISMUTH SALICYLATE; CONGO RED; IMMUNOLOGIC AGENT; LANSOPRAZOLE; METRONIDAZOLE;

CHEMOTHERAPY; GERMANY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IMMUNOLOGY; LABORATORY; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STAIN; SYPHILIS;

ANTITREPONEMAL AGENTS; ARSPHENAMINE; COLORING AGENTS; DRUG RESISTANCE, MICROBIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALARIA; METHYLENE BLUE; SYPHILIS;

EID: 1842851879     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077277     Document Type: Review

References (12)

1. The Nomination Database for the Nobel Prize in Physiology or Medicine, 1901-1949. The Official Web Site of The Nobel Foundation. Copyright® 2003 The Nobel Foundation. http://www.nobel.se/medicine/nomination/database. html.
2. Burstein GR, Workowski KA: Sexually transmitted diseases treatment guidelines. Curr Opin Pediatr 2003;15:391-397.
3. Rekart ML, Patrick DM, Chakraborty B, Maginley JJ, Jones HD, Bajdik CD, Pourbohloul B, Brunham RC: Targeted mass treatment for syphilis with oral azithromycin. Lancet 2003;361:313-314.
4. Kingston M, Carlin E: Treatment of sexually transmitted infections with single-dose therapy: A double-edged sword. Drugs 2002;62:871-878.
5. Coates A, Hu Y, Bax R, Page C: The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov 2002;1:895-910.
6. Drusano GL: Prevention of resistance: A goal for dose selection for antimicrobial agents. Clin Infect Dis 2003;36(suppl 1):S42-S50.
7. Andes D, Craig WA: Animal model pharmacokinetics and pharmacodynamics: A critical review. Int J Antimicrob Agents 2002;19:261-268.
8. Polk R: Can we use the clinical pharmacology of antibacterial drugs to predict (and prevent) the propensity for development of antimicrobial resistance? Presented at the 103rd General Meeting, American Society for Microbiology Annual Meeting, Washington, D.C., May 21, 2003.
9. Lara LF, Cisneros G, Gurney M, Van Ness M, Jarjoura D, Moauro B, Polen A, Rutecki G, Whittier F: One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection. Arch Intern Med 2003;163:2079-2084.
10. Douer D, Hu W, Giralt S, Lill M, DiPersio J: Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation. Oncologist 2003;8:132-140.
11. Sörgel F: World Conference on Dosing of Antiinfectives: 'Dosing the Magic Bullets'. Celebrating the 150th Birthday of Paul Ehrlich, the 'Founder of Chemotherapy', September 9-11, 2004, Nürnberg, Germany. Chemotherapy 2004;50:1-5.
12. Sanchez I, Mahlke C, Yuan J: Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003; 421:373-379.